Paper39645477
Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis.
Metcalf A and 5 others. J Cyst Fibros, 2025. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis. Papers, record 39645477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39645477
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aminophenols | Major topic |
| Cystic Fibrosis | Major topic |
| Fetal Diseases | Major topic |
| Indoles | Major topic |
| Meconium Ileus | Major topic |
| Pyrazoles | Major topic |
| Pyridines | Major topic |
| Adult | |
| Female | |
| Humans | |
| Infant, Newborn | |
| Male | |
| Pregnancy | |
| Benzodioxoles | |
| Chloride Channel Agonists | |
| Drug Combinations | |
| Pyrrolidines | |
| Quinolones | |
| Treatment Outcome | |
| Quinolines |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42890452 | Early nutritional management of cystic fibrosis infants born with meconium ileus. | JPGN Rep | 2026 | https://conductscience.org/library/papers/42890452 | PubMed |
| 42819752 | Prenatal CFTR modulator therapy for fetal cystic fibrosis: Emerging evidence, clinical considerations, and future directions. | Pregnancy (Hoboken) | 2026 | https://conductscience.org/library/papers/42819752 | PubMed |
| 42778208 | Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review. | Eur Respir Rev | 2026 | https://conductscience.org/library/papers/42778208 | PubMed |
| 42452421 | In Utero Molecular-Targeted Drug Therapies: Translational Principles, Pharmacologic Considerations, and Emerging Clinical Applications. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452421 | PubMed |
| 42092016 | Opportunities for antenatal medical treatment of genetic conditions: the earlier, the better. | Pediatr Res | 2026 | https://conductscience.org/library/papers/42092016 | PubMed |
| 42084532 | Utility of Fecal Elastase-1 in Estimating Exocrine Pancreatic Function in Cystic Fibrosis: A Scoping Review. | Pediatr Pulmonol | 2026 | https://conductscience.org/library/papers/42084532 | PubMed |
| 42057868 | Management of Infants Exposed to Prenatal and Postnatal Elexacaftor/Tezacaftor/Ivacaftor: A Cross-Sectional Survey. | Health Sci Rep | 2026 | https://conductscience.org/library/papers/42057868 | PubMed |
| 42015944 | Discrepant Results on Two Different Single Gene Non-invasive Prenatal Tests for Cystic Fibrosis: A Case Report. | AJP Rep | 2026 | https://conductscience.org/library/papers/42015944 | PubMed |
| 41976926 | Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. | J Clin Med | 2026 | https://conductscience.org/library/papers/41976926 | PubMed |
| 41829909 | Early Life Nutrition: The First 1000 Days and Healthy Aging in Cystic Fibrosis. | Nutrients | 2026 | https://conductscience.org/library/papers/41829909 | PubMed |
| 41827350 | Antenatal CFTR Modulators to Treat a Healthy Pregnant Woman with a Fetus Affected by Cystic Fibrosis Complicated by Meconium Ileus and Intestinal Volvulus: From a Suspicion of the Disease to a Targeted Treatment in Utero: Case Report and Narrative Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/41827350 | PubMed |
| 41731048 | A therapeutic revolution: CFTR modulators in cystic fibrosis and their impacts on pregnant women and the fetus. | J Perinatol | 2026 | https://conductscience.org/library/papers/41731048 | PubMed |
| 41588096 | The evolving understanding of cystic fibrosis-related diabetes in the highly effective modulator therapy era: a scoping review. | Diabetologia | 2026 | https://conductscience.org/library/papers/41588096 | PubMed |
| 41314865 | Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. | J Cyst Fibros | 2026 | https://conductscience.org/library/papers/41314865 | PubMed |
| 40961131 | The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy. | Ann Am Thorac Soc | 2026 | https://conductscience.org/library/papers/40961131 | PubMed |
| 40778614 | Cystic Fibrosis Year in Review 2024. | Pediatr Pulmonol | 2025 | https://conductscience.org/library/papers/40778614 | PubMed |
| 40320452 | Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators. | Mol Cell Pediatr | 2025 | https://conductscience.org/library/papers/40320452 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39645477
GET https://conductscience.org/api/papers/v1/39645477/authors